Yael Margolin | Chief Executive Officer
Gamida Cell Ltd

Yael Margolin, Chief Executive Officer, Gamida Cell Ltd

Dr. Margolin has more than 35 years of experience in the venture capital, pharmaceutical and biotech industries. As a senior manager, skilled scientist and experienced board member, she possesses a highly developed combination of leadership, decision-making and business skills. Dr. Margolin has served as president & CEO of Gamida Cell since 2005. During this time, she has led Gamida Cell from pre-clinical development through phase 3 international registration studies, the receipt of a Breakthrough Therapy Designation for the company’s lead product, strategic collaborations and the raising of $100 million from various financing initiatives. Dr. Margolin previously served as vice president of Denali Ventures LLC, a healthcare specialized venture capital firm, and a program manager at Teva Pharmaceuticals, leading multiple drug development programs. Dr. Margolin holds a Ph.D. in Biology from the Weizmann Institute of Science and was a post-doctoral associate at the Yale University School of Medicine.


Cord Blood Day 1- Wednesday 16th May 2018 @ 17:20

NiCord® Breakthrough Therapy Designation - addressing the unmet need in BMT with a novel graft modality

  • NiCord is an ex vivo expanded cell graft derived from umbilical cord stem cells 
  • A phase 3 randomized controlled multi-national registration study is enrolling patients
  • NiCord is expected to double the number of indicated patients to transplant

back to speakers

World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257